COVID-19 vaccination is associated with a small, temporary increase in menstrual cycle length; CMS announced a 3% reduction in Medicare Part B premiums; Johnson & Johnson (J&J) announced Kenvue as the name of its new consumer health company set to launch next year.
A large study funded by the National Institutes of Health confirmed findings from a previous study linking COVID-19 vaccination with a small temporary increase in menstrual cycle length. The study included nearly 20,000 people from North America and Europe and found an average increase in menstrual cycle length of less than 1 day, but this increase was not associated with changes in the number of days of menstrual bleeding. Compared with individuals who did not receive a COVID-19 vaccine and compared with at least 3 cycles prior to vaccination, individuals experienced a .71 day increase in cycle length after their first dose and a .56 day increase after their second dose, on average. Those who received both doses in a single cycle saw the greatest change in menstrual cycle length, with a 3.91 day increase, on average. The study included 9 different vaccines and found no changes based on which vaccine an individual received. More research is needed to understand why these changes are occurring.
The Biden administration announced a reduction in Medicare Part B premiums in 2023, marking the first time these costs will be lowered since 2012, The Hill reported. CMS specifically said there will be a 3%, or $5.20, reduction, with premiums going from $170.10 to $164.90 per month. The annual deductible will also drop by $7, from $233 to $226. The year 2022 saw the greatest increase in Medicare Part B premiums with a 14.5% increase linked to the FDA-approval of Alzheimer drug Adulhelm.
Johnson & Johnson (J&J) announced Kenvue as the name of its new consumer health company set to launch in 2023. J&J’s consumer health segment generated $14.6 billion in revenue in 2021, and Kenvue as a standalone company is expected to generate sales in over 100 countries. In the news release, J&J noted this planned separation is subject to legal requirements, such as consultations with works councils and employee representatives.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
2 Commerce Drive
Cranbury, NJ 08512